Protocol Ledger

NCT07154264 · Phase II · RECRUITING

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

Interventional Phase II clinical trial protocol NCT07154264 sponsored by Dizal Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-09-22 Enrollment: 66 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07154264
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)66 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07154264
Protocol FieldVerified Registry Value
NCT IdentifierNCT07154264
Consolidated Lead SponsorDizal Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment66 participants (ESTIMATED)
Registered Start Date2025-09-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI